129 related articles for article (PubMed ID: 35008307)
1. YK-4-279 Attenuates Progression of Pre-Existing Pigmented Lesions to Nodular Melanoma in a Mouse Model.
Huang L; Zhai Y; Fajardo CD; Lang D
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008307
[TBL] [Abstract][Full Text] [Related]
2. A small molecule inhibitor of ETV1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model.
Rahim S; Minas T; Hong SH; Justvig S; Çelik H; Kont YS; Han J; Kallarakal AT; Kong Y; Rudek MA; Brown ML; Kallakury B; Toretsky JA; Üren A
PLoS One; 2014; 9(12):e114260. PubMed ID: 25479232
[TBL] [Abstract][Full Text] [Related]
3. p53 Loss Mediates Hypersensitivity to ETS Transcription Factor Inhibition Based on PARylation-Mediated Cell Death Induction.
Dinhof C; Pirker C; Kroiss P; Kirchhofer D; Gabler L; Gojo J; Lötsch-Gojo D; Stojanovic M; Timelthaler G; Ferk F; Knasmüller S; Reisecker J; Spiegl-Kreinecker S; Birner P; Preusser M; Berger W
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33143299
[TBL] [Abstract][Full Text] [Related]
4. The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents.
Spriano F; Chung EYL; Gaudio E; Tarantelli C; Cascione L; Napoli S; Jessen K; Carrassa L; Priebe V; Sartori G; Graham G; Selvanathan SP; Cavalli A; Rinaldi A; Kwee I; Testoni M; Genini D; Ye BH; Zucca E; Stathis A; Lannutti B; Toretsky JA; Bertoni F
Clin Cancer Res; 2019 Aug; 25(16):5167-5176. PubMed ID: 31182435
[TBL] [Abstract][Full Text] [Related]
5. The ETS Inhibitor YK-4-279 Suppresses Thyroid Cancer Progression Independent of
Xue J; Li S; Shi P; Chen M; Yu S; Hong S; Li Y; Liu R; Xiao H
Front Oncol; 2021; 11():649323. PubMed ID: 34221969
[TBL] [Abstract][Full Text] [Related]
6. An inhibitor of endothelial ETS transcription factors promotes physiologic and therapeutic vessel regression.
Schafer CM; Gurley JM; Kurylowicz K; Lin PK; Chen W; Elliott MH; Davis GE; Bhatti F; Griffin CT
Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26494-26502. PubMed ID: 33020273
[TBL] [Abstract][Full Text] [Related]
7. An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma.
Lamhamedi-Cherradi SE; Menegaz BA; Ramamoorthy V; Aiyer RA; Maywald RL; Buford AS; Doolittle DK; Culotta KS; O'Dorisio JE; Ludwig JA
Mol Cancer Ther; 2015 Jul; 14(7):1591-604. PubMed ID: 25964201
[TBL] [Abstract][Full Text] [Related]
8. The Efficiency of Verteporfin as a Therapeutic Option in Pre-Clinical Models of Melanoma.
Lui JW; Xiao S; Ogomori K; Hammarstedt JE; Little EC; Lang D
J Cancer; 2019; 10(1):1-10. PubMed ID: 30662519
[TBL] [Abstract][Full Text] [Related]
9. Preclinical studies of YK-4-272, an inhibitor of class II histone deacetylases by disruption of nucleocytoplasmic shuttling.
Kong HS; Tian S; Kong Y; Du G; Zhang L; Jung M; Dritschilo A; Brown ML
Pharm Res; 2012 Dec; 29(12):3373-83. PubMed ID: 22836184
[TBL] [Abstract][Full Text] [Related]
10. Differences in tumor initiation and progression of melanoma in the Braf
Zhai Y; Haresi AJ; Huang L; Lang D
Pigment Cell Melanoma Res; 2020 Jan; 33(1):119-121. PubMed ID: 31449725
[No Abstract] [Full Text] [Related]
11. YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion.
Rahim S; Beauchamp EM; Kong Y; Brown ML; Toretsky JA; Üren A
PLoS One; 2011 Apr; 6(4):e19343. PubMed ID: 21559405
[TBL] [Abstract][Full Text] [Related]
12. Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in Pten
Deken MA; Song JY; Gadiot J; Bins AD; Kroon P; Verbrugge I; Blank CU
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999416
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma.
Hong SH; Youbi SE; Hong SP; Kallakury B; Monroe P; Erkizan HV; Barber-Rotenberg JS; Houghton P; Üren A; Toretsky JA
Oncotarget; 2014 Jan; 5(2):338-50. PubMed ID: 24481407
[TBL] [Abstract][Full Text] [Related]
14. Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib.
Cohen PR; Bedikian AY; Kim KB
J Clin Aesthet Dermatol; 2013 May; 6(5):27-37. PubMed ID: 23710269
[TBL] [Abstract][Full Text] [Related]
15. Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.
Bonet C; Luciani F; Ottavi JF; Leclerc J; Jouenne FM; Boncompagni M; Bille K; Hofman V; Bossis G; Marco de Donatis G; Strub T; Cheli Y; Ohanna M; Luciano F; Marchetti S; Rocchi S; Birling MC; Avril MF; Poulalhon N; Luc T; Hofman P; Lacour JP; Davidson I; Bressac-de Paillerets B; Ballotti R; Marine JC; Bertolotto C
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376192
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of ERG Activity in Patient-derived Prostate Cancer Xenografts by YK-4-279.
Winters B; Brown L; Coleman I; Nguyen H; Minas TZ; Kollath L; Vasioukhin V; Nelson P; Corey E; Üren A; Morrissey C
Anticancer Res; 2017 Jul; 37(7):3385-3396. PubMed ID: 28668826
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of YK-176 (2'-deoxycoformycin) in patients with adult T-cell leukemia-lymphoma. The DCF Study Group.
Tobinai K; Shimoyama M; Inoue S; Takayasu S; Mikuni C; Kozuru M; Oda S; Nakajima H
Jpn J Clin Oncol; 1992 Jun; 22(3):164-71. PubMed ID: 1518164
[TBL] [Abstract][Full Text] [Related]
18. Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1.
Barber-Rotenberg JS; Selvanathan SP; Kong Y; Erkizan HV; Snyder TM; Hong SP; Kobs CL; South NL; Summer S; Monroe PJ; Chruszcz M; Dobrev V; Tosso PN; Scher LJ; Minor W; Brown ML; Metallo SJ; Üren A; Toretsky JA
Oncotarget; 2012 Feb; 3(2):172-82. PubMed ID: 22383402
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of 1alpha-hydroxyvitamin D2 in inhibiting tumor growth in a murine transgenic pigmented ocular tumor model.
Albert DM; Kumar A; Strugnell SA; Darjatmoko SR; Lokken JM; Lindstrom MJ; Damico CM; Patel S
Arch Ophthalmol; 2004 Sep; 122(9):1365-9. PubMed ID: 15364717
[TBL] [Abstract][Full Text] [Related]
20. ETS-1 and ETS-2 are upregulated in a transgenic mouse model of pigmented ocular neoplasm.
De la Houssaye G; Vieira V; Masson C; Beermann F; Dufier JL; Menasche M; Abitbol M
Mol Vis; 2008; 14():1912-28. PubMed ID: 18958307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
